About ZemairaWhat is Alpha-1?Patient SupportAlpha-1 Guardian ProgramSpecialty Pharmacy PartnersCSL Behring AssuranceReimbursement ResourcesZemaira Plant TourMy Steps for Healthy LivingWalk For Breath CelebrationPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

Specialty Pharmacy Partners

CSL Behring is pleased to provide expanded distribution and availability of Zemaira® through our partnerships with leading specialty pharmacies for respiratory patients, Accredo Therapeutics and Coram, Inc. (a division of Apria Healthcare). These partnerships help to ensure that people who rely on Zemaira® will have continued access to their therapy.

Depending on your insurance coverage, your personal preference, and what you and your healthcare provider decide is best for you, you may receive your infusions in:

  • Your home
  • A hospital outpatient department
  • A freestanding infusion clinic or center

Our Specialty Pharmacy Partners will work with you to help you get your therapy when and where you need it.

For more information about service with Accredo Therapeutics call
866-6ALPHA1 (866-625-7421) or visit www.accredotx.com.

For more information about service with Coram call 866-FORA1PI (866-367-2174)
or visit www.coramhc.com.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.